{
"@context": "https://schema.org",
"@type": "Article",
"headline": "FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI®",
"url": "https://www.lexblog.com/2024/02/02/fdas-office-of-prescription-drug-promotion-issues-its-first-untitled-letter-of-the-year-to-novartis-for-misleading-statement-relating-to-kisqali-2/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-S1MXPJXG",
"url": "https://www.lexblog.com/lib/S1MXPJXG/"
},
"datePublished": "2024-02-02T17:36:16-05:00",
"dateModified": "2024-02-02T14:36:50-05:00",
"author": {
"@type": "Person",
"name": "Dominick DiSabatino, Eve Costopoulos, Cortney Inman"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Sheppard, Mullin, Richter & Hampton LLP"
},
"organizationScope": "at-publication",
"about": "Food, Drug & Agriculture",
"sourceUrl": "https://www.fdalawblog.com/?p=2160",
"sourceStability": "may-move"
}